#lateral flow

According to a new market research report titled "Rapid Diagnostics Market by Product (Kits [OTC, Professional], Readers), Platform (Lateral Flow, Serological, PCR), Application (Blood Glucose, Infectious Diseases, Pregnancy, Drugs of Abuse), End User (Hospitals, Diagnostic Labs, Home Care) — Global Forecasts to 2029", published by Meticulous Research®, the rapid diagnostics market is expected to grow at a CAGR of 8.9% from 2022–2029 to reach $18.20 billion by 2029.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5240

A rapid diagnostic test (RDT) is a medical diagnostic test intended to provide diagnostic results efficiently and immediately (within 1 hour). RDT kits are widely used in hospitals, clinics, and diagnostic laboratories for the qualitative and quantitative detection of specific antigens, antibodies, and genetic material or proteins associated with a specific health condition or disease.

The growth of the overall RDT market is driven by key factors, such as the growing demand for POC diagnostics, the rising prevalence of chronic diseases coupled with the increasing aging population, the growing necessity for rapid decision making in emergency departments, and emerging technological innovations.

Rapid Diagnostics Market: Outlook

The overall rapid diagnostics market is segmented based on product (kits and test readers/analyzers), platform (immunoassays, molecular detection, and other platforms), application (blood glucose testing, cardiac metabolism testing, infectious diseases testing, coagulation testing, pregnancy & fertility testing, fecal occult testing, hematology testing, tumor/cancer markers testing, drugs of abuse testing, urinalysis, and cholesterol testing), end user (hospitals & clinics, diagnostic laboratories, home care/self testing, and other end users) and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). The study also evaluates industry competitors and analyzes their market shares at the global and regional levels.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5240

Based on product type, the kits segment is estimated to account for the largest share of the overall rapid diagnostics market in 2022. The large share of this segment is attributed to the rising adoption and repetitive kits usage. In addition, the growing portfolio of disease-specific kits for the early diagnosis of chronic diseases and the increasing technological advancements are other factors supporting the growth of this segment. However, the test readers/analyzers segment is expected to witness the fastest growth rate during the forecast period. The high growth rate of this segment is attributed to the capabilities of these devices to simultaneously read multiple tests in one scan and scale large volumes. In addition, healthcare facilities adopt analyzers for quick analysis compared to centralized lab analyzers due to their features, such as compact size, portability, and easy accessibility.

Based on platform, the immunoassays segment is estimated to account for the largest share of the overall rapid diagnostics market in 2022. The large share of this segment is attributed to the capability of immunoassay kits to provide fast and accurate results with high sensitivity in point-of-care diagnostics. Countries worldwide require rapid and accurate SARS-CoV-19 testing kits to tackle the COVID-19 pandemic. Thus, companies have started developing immunoassay kits that provide results with higher sensitivity, accuracy, and speed. For instance, in May 2021, Stream Bio (U.K.) and Chelsea Technologies (U.K.) formed a joint venture, Brightline Diagnostics (DX), and created a unique platform known as Claritas that couples fluorescent lateral flow test with a highly sensitive handheld reader, delivering significant advantages over existing assays. However, the molecular detection segment is expected to witness the fastest growth rate during the forecast period. The growing need for advanced diagnostic techniques and the launch of innovative technologies are factors attributed to the high growth rate of this segment. In addition, the high demand for rapid PCR diagnostic kits due to the COVID-19 pandemic further boost the growth of this segment. For instance, countries such as Japan and India rely heavily on RT-PCR kits to diagnose and manage COVID-19 infections. Also, numerous countries worldwide have made negative COVID-19 RT-PCR test reports mandatory for international and local travelers.

Quick Buy – Rapid Diagnostics Market Research Report: https://www.meticulousresearch.com/Checkout/74262428

Based on application, the infectious disease testing segment is estimated to account for the largest share of the rapid diagnostics market in 2022. The large share of this segment is mainly attributed to the rising prevalence of infectious diseases and the growing demand for affordable infectious disease testing in emerging markets. For instance, in the U.S., the number of estimated new hepatitis A virus (HAV) infections increased by nearly three folds in 2017 compared to 2014. However, the tumor/cancer markers testing segment is expected to witness the fastest growth rate during the forecast period. The growing incidences of cancer among the general population is the major factor attributed to the high growth rate of this segment. According to WHO, cancer was the leading cause of death globally in 2020, accounting for approximately 10 million deaths. Furthermore, nearly 70% of deaths out of the total deaths from cancer occur in low- and middle-income countries; therefore, early detection is extremely important to reduce mortality, enhance survival, and save treatment costs. Thus, healthcare workers utilize various rapid diagnostic kits for the early detection of cancer.

Based on end user, the hospitals & clinics segment is expected to witness the fastest growth rate in the forecast period. The rising number of hospitals worldwide and the increase in healthcare access & expenditure are attributed to the high growth rate of this segment. For instance, the American Hospital Association has reported that the total number of registered hospitals in the U.S. was estimated to grow by 12% to 6,210 in 2019 from 5,534 hospitals in 2018. Similarly, in India, according to the Health Management Information System Portal (HMIS), as of 2018, there were around 37,725 hospitals, which was an increase of 7.0% from 35,416 hospitals in 2013.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5240

Geographically, North America is estimated to command the largest share of the global rapid diagnostics market in 2022, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa. The large market share of this region is mainly attributed to the high number of laboratory tests performed annually in North America, the rising prevalence of chronic diseases coupled with the increasing aging population, and the rising number of inpatient hospitalizations. For instance, the U.S. Department of Health and Human Services reported that the number of patients with HIV is growing with a CAGR of 2.5% in the country. It is assumed that 40% of new HIV infections in the U.S. are transmitted by people living with undiagnosed HIV; this boosts the demand for related rapid testing products throughout the country.

However, Asia-Pacific region is expected to be the fastest-growing regional market due to the growing geriatric population, the rising prevalence of infectious & chronic diseases, and various government initiatives to promote health awareness.

Key companies operating in the global rapid diagnostics market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), ACON Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), BioMérieux S.A. (France), Alfa Scientific Designs, Inc. (U.S.), BTNX Inc. (Canada), Meridian Bioscience, Inc. (U.S.), and Trinity Biotech plc (Ireland) among others.

Covid: NHS bosses call for free tests and isolation to remain – BBC News

I agree now is not the time to getting rid of free COVID test neither PCR or Lateral flow, as in health and social care regular testing needs to  be continued and also for the general population. If they are not free the costs to the NHS and social care would be tremendous and would take too much funding away for actual caring. Social Care is already on its knees and may not survive and would…

COVID jab, Done and done. Glad it’s all sorted. Just have to wait for M to have his final one and we are safe to start living again. On saying all that we have no interest in going to the pubs, clubs or on holiday at the moment. Knowing our luck we would book a holiday and then the world would go to hell again and everything would be cancelled. I am hoping that my reaction to the jab is the same…

COVID jab, Done and done. Glad it’s all sorted. Just have to wait for M to have his final one and we are safe to start living again. On saying all that we have no interest in going to the pubs, clubs or on holiday at the moment. Knowing our luck we would book a holiday and then the world would go to hell again and everything would be cancelled. I am hoping that my reaction to the jab is the same…

From late December 2019, coronavirus irresistible infection (COVID‐19) pandemics spread from Wuhan, China, to everywhere throughout the world, including Italy. 1, 2, 3 

Until now, real‐time switch transcription‐polymerase chain response (RT‐PCR) in respiratory examples is the current best quality level technique for the finding of COVID‐19. 4, 5 However, atomic testings are tedious and require specific administrators, factors that limit their utilization, all things considered, when the quick analysis is required for quick intercession choices. As of late, simple to perform serological test has been evaluated 6 to separate COVID‐19 positive patients from negative subjects. 

We thus report aftereffects of a real‐life study acted in a crisis room division of a tertiary clinic in Northern Italy to approve the VivaDiag COVID‐19 IgM/IgG Rapid Test parallel stream immunoassay (LFIA) for the fast determination of COVID‐19. 

Generally speaking, 110 subjects were tried for the COVID‐19‐specific serological test at Fondazione IRCCS Policlinico San Matteo. In detail, we selected 30 solid volunteers with archived negative outcomes for COVID‐19 RT‐PCR in respiratory examples (M 11/F 19; middle age, 38.5; territory, 25‐69 years). Ten of them (33.3%) had been contaminated in the past with one of the normal OC43, 229E, HKU1, and NL63 coronavirus. Thirty COVID‐19‐positive patients (25 M/5 F; middle age, 73.5; territory, 38‐86 years) admitted to the Infectious Diseases Department or at the Intensive Care Unit were tried as positive controls. At last, the presentation of VivaDiag COVID‐19 IgM/IgG Rapid Test LFIA was tried in 50 patients at their first access at crisis room office with a fever and respiratory condition (34 M/16 F; middle age, 61.50; territory, 33‐97 years) in examination with aftereffects of nasal swab sub-atomic screening. 5 

VivaDiag COVID‐19 IgM/IgG from VivaChek was performed by maker's guidance by including 10 µL of serum or entire blood test into the example port followed by adding 2 to 3 drops (70‐100 µL) of weakening support. 6 After about 15 minutes, results were perused. 

Respiratory examples (FLOQSwabs; Copan Italia, Brescia, Italy) were gathered from all the patients. Complete nucleic acids (DNA/RNA) were separated from 200 µL of UTM utilizing the QIAsymphony instrument with QIAsymphony DSP Virus/Pathogen Midi Kit (complex 400 conventions) as indicated by the maker's directions (QIAGEN; Qiagen, Hilden, Germany). Explicit real‐time RT‐PCR focusing on RNA‐dependent RNA polymerase and Equalities were utilized to identify the nearness of SARS‐CoV‐2 as indicated by the WHO rules 7 and Corman et al 5 conventions. 

In the accomplice of patients admitted to the crisis room office, information from serological tests were contrasted with atomic outcomes to characterize explicitness, affectability, positive prescient worth (PPV), and negative prescient worth (NPV) of the quick serological test. 

True to form, every one of the 30 COVID‐19 negative volunteers was negative for both immunoglobulin G (IgG) and immunoglobulin M (IgM) utilizing the VivaDiag COVID‐19 IgM/IgG Rapid Test. No cross‐reactivity was recognized in the 10 subjects with past coronaviruses disease, supporting the high explicitness of the VivaDiag COVID‐19 IgM/IgG Rapid Test LFIA. 

Serum tests were acquired at a middle 7 days (interquartile extend, 4‐11) after the main COVID‐19 positive outcome from 30 hospitalized patients. A sum of 19 of 30 (63.3%) was sure for both IgM and IgG, 5 of 30 (16.7%) were negative for both IgG and IgM, 5 of 30 (16.7%) were feebly positive for both IgM and IgG, and just 1 of 30 (3.3%) was sure for IgM and negative for IgG. In this manner, the affectability of the quick test was imperfect (information not are appeared). A potential clarification is the low immunizer titers or a postponed humoral reaction. 6 

Concentrating on intense patients selected from the crisis room division, 12 of 50 (24%) were negative for COVID‐19 by real‐time RT‐PCR. Of these, 1 (8.3%) indicated positive outcomes for the VivaDiag COVID‐19 IgM/IgG Rapid Test, while the other 11 of 12 (91.7%) tried negative. 

On the opposite side, 38 patients were sure for COVID‐19 by real‐time RT‐PCR. Of these, lone 7 (18.4%) indicated a positive or powerless positive serology for IgM or potentially IgG, while the other 31 of 38 (81.6%) tried negative for the fast serology measure (Table 1). 

In this way, the affectability of the VivaDiag COVID‐19 IgM/IgG Rapid Test was 18.4%, particularity was 91.7%, while NPV was 26.2%, and PPV was 87.5% in patients selected from crisis room office. 

Interestingly with the significant levels of affectability announced in the past examination, 6 VivaDiag COVID‐19 IgM/IgG Rapid Test uncovered an extremely poor affectability (under 20%). To be sure, most of the patients that tried positive for COVID‐19 by real‐time RT‐PCR would have been recognized as negative utilizing just the quick serological test, prompting a misdiagnosis of COVID‐19 malady in by far most of the patients. 

Based on our outcomes, VivaDiag COVID‐19 IgM/IgG Rapid Test LFIA isn't suggested for triage of patients with suspected COVID‐19.

Lateral Flow Assay Market Forecast 2017-2022 and Key Companies are Studied in a Latest Report

Read Detailed Market Report @https://www.reportsandmarkets.com/reports/global-lateral-flow-assay-detailed-analysis-report-2017-2022-1571715 The Reports and Market Provide this report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and…